Vaccine List

AFLURIA is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza virus subtypes A and type B present in the vaccine. AFLURIA is approved for use in persons 6 months of age and older.  AFLURIA is contraindicated in individuals with known...Read more...

NuThrax™, anthrax vaccine adsorbed with CPG 7909 adjuvant, in the event of a public health emergency involving Bacillus anthracis.

BARDA Securing Anthrax Immunity For the Elderly (B-SAFE)  This study is designed...Read more...

BOOSTRIX is a vaccine indicated for active booster immunization against tetanus, diphtheria, and pertussis. BOOSTRIX is approved for use as a single dose in individuals 10 years of age and older. A severe allergic reaction after a previous dose of any tetanus toxoid-, diphtheria toxoid-, or...Read more...

DAPTACEL is a vaccine indicated for active immunization against diphtheria, tetanus, and pertussis as a five-dose series in infants and children 6 weeks through 6 years of age (prior to 7th birthday). DAPTACEL is to be administered as a 5 dose series at 2, 4 and 6 months of age (at intervals of...Read more...

ENGERIX-B is a vaccine indicated for immunization against infection caused by all known subtypes of hepatitis B virus. Primary immunization for infants (born of hepatitis B surface antigen [HBsAg]-negative or HBsAg-positive mothers), children (birth through 10 years), and adolescents (aged 11...Read more...

FLUAD is a vaccine that helps protect against the flu. FLUAD is for people aged 65 years and older. Vaccination with FLUAD may not protect all people who receive the vaccine.Read more...

Flublok and Flublok Quadrivalent vaccines are given to people 18 years of age and older to help prevent influenza disease caused by influenza A virus subtypes and influenza type B virus contained in the vaccine. Read more...

Flucelvax Tetra will be the first cell-based quadrivalent influenza vaccine (QIVc) available in Europe. The cell-based technology represents one of the most momentous changes in the way influenza vaccines are manufactured since the 1940s.Read more...

The Advisory Committee on Immunization Practices (ACIP) recommended that FluMist Quadrivalent not be used for the 2016-2017 season. FluMist Quadrivalent is a vaccine that is sprayed into the nose to help protect against influenza. It can be used in children, adolescents, and adults ages 2...Read more...

Fluzone Quadrivalent, Fluzone Intradermal Quadrivalent, and Fluzone High-Dose vaccines are given to help prevent influenza disease caused by influenza A and B strains contained in each vaccine. Fluzone Quadrivalent vaccine is given to people 6 months of age and older. Fluzone...Read more...

Fluzone Quadrivalent, Fluzone Intradermal Quadrivalent, and Fluzone High-Dose vaccines are given to help prevent influenza disease caused by influenza A and B strains contained in each vaccine. Fluzone Intradermal Quadrivalent vaccine is given to people 18...Read more...

GARDASIL is a vaccine indicated in girls and women 9 through 26 years of age for the prevention of the following diseases caused by Human Papillomavirus (HPV) types included in the vaccine: Cervical, vulvar, vaginal, and anal cancer caused by HPV types 16 and 18, Genital warts (condyloma...Read more...

HARVONI is a prescription medicine used to treat adults with chronic (lasting a long time) hepatitis C (Hep C) genotype (GT) 1, 4, 5 or 6 infection with or without cirrhosis (compensated). In those with GT 1 and advanced cirrhosis (decompensated) or with GT 1 or 4 with or without cirrhosis (...Read more...

HepaGam B® [Hepatitis B Immune Globulin Intravenous (Human)] is an intravenous immune globulin indicated for the following: Prevention of Hepatitis B recurrence following liver transplant in HBsAg-positive liver transplant patients.  Post-exposure prophylaxis...Read more...

HydroVax-001 experimental vaccine was discovered and developed by scientists at the Oregon National Primate Research Center at Oregon Health & Science University (OHSU) in Portland.

The scientists were funded with a $7.2 million grant awarded in 2009 from NIAID, part of the National...Read more...

INFANRIX is a vaccine indicated for active immunization against diphtheria, tetanus, and pertussis as a 5-dose series in infants and children 6 weeks to 7 years of age (prior to seventh birthday).Read more...

FluGen’s M2SR vaccine utilizes a proprietary M2 deleted, single replication (M2SR) influenza virus.

The M2 gene is essential for the influenza virus to spread in the patient and the deletion of the M2 gene restricts the virus to a single replication cycle in the host.

The body...Read more...

Menactra vaccine is indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135. Menactra vaccine is approved for use in individuals 9 months through 55 years of age. Menactra vaccine does not prevent N meningitidis...Read more...

MENVEO is a vaccine indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135. MENVEO is approved for use in persons 2 months through 55 years of age. MENVEO does not prevent N. meningitidis serogroup B infections...Read more...

Mosquirix is a vaccine that is given to children aged 6 weeks to 17 months to help protect against malaria caused by the parasite Plasmodium falciparum.

The vaccine should only be used in areas of the world where malaria caused by Plasmodium falciparum is prevalent, and according to...Read more...

Novavax's NanoFlu is an influenza vaccine candidate in a phase 2 clinical study.

The trial compared the safety and immune responses of various quadrivalent formulations of NanoFlu, with or without Novavax’...Read more...

Nexvax2 is being developed to protect celiac disease (CeD) patients who carry the HLA-DQ2.5 immune recognition genes, from inadvertent gluten exposure.

Patients with the HLA-DQ2.5 genes account for more than 90% of the CeD population.

A global...Read more...

PEDIARIX is a vaccine indicated for active immunization against diphtheria, tetanus, pertussis, infection caused by all known subtypes of hepatitis B virus, and poliomyelitis. PEDIARIX is approved for use as a three-dose series in infants born of hepatitis B surface antigen (HBsAg)-negative...Read more...

PENNVAX®-GP is a developmental vaccine to prevent and treat HIV strains primarily present in Africa, Asia, Europe, and North America. It is intended to induce broad antibody and T-cell immune responses. This multi-subtype vaccine is based on optimized synthetic immunogens targeting two env...Read more...

PNEUMOVAX ® 23 (Pneumococcal Vaccine Polyvalent) is a vaccine indicated for active immunization for the prevention of pneumococcal disease caused by the 23 serotypes contained in the vaccine (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F)....Read more...

ProQuad is a vaccine indicated for active immunization for the prevention of measles, mumps, rubella, and varicella in children 12 months through 12 years of age.Read more...

Quadracel vaccine is indicated for active immunization against diphtheria, tetanus, pertussis, and poliomyelitis. A single dose of Quadracel vaccine is approved for use in children 4 through 6 years of age as a fifth dose in the diphtheria, tetanus, pertussis vaccination (DTaP) series, and as a...Read more...

RECOMBIVAX HB is indicated for prevention of infection caused by all known subtypes of hepatitis B virus. RECOMBIVAX HB is approved for use in individuals of all ages. RECOMBIVAX HB Dialysis Formulation is approved for use in adult predialysis and dialysis patients 18 years of age and older.Read more...

ROTARIX is a vaccine indicated for the prevention of rotavirus gastroenteritis caused by G1 and non-G1 types (G3, G4, and G9) when administered as a 2-dose series. ROTARIX is approved for use in infants 6 weeks to 24 weeks of age.Read more...

The scMAYV-E DNA vaccine was administered to mice by intramuscular injection followed by pulses of electricity designed to make cells more permeable to foreign DNA and enhance vaccine uptake, which allows for dose-sparing.

Immunization with scMAYV-E induced robust MAYV-specific immune...Read more...

Sanofi Pasteur confirms that YF-VAX® (Yellow Fever Vaccine) is unavailable to order in the U.S. until mid-2018 as the company transitions production to a new state-of-the-art facility, which is expected to occur in 2018. Sanofi Pasteur has worked with the FDA to make another yellow fever vaccine...Read more...

TRUVADA for PrEP (pre-exposure prophylaxis) is a prescription medicine that is used together with safer sex practices to help reduce the risk of getting HIV-1 through sex. This use is only for HIV-negative adults who are at high risk of getting HIV-1. To help determine your risk of getting HIV-1...Read more...

TYPHIM Vi is manufactured by Sanofi Pasteur for intramuscular use for protection against Typhoid Fever. It is a sterile solution, prepared from the purified polysaccharide capsule of Salmonella typhi (Ty 2 strain). The purified polysaccharide capsule is diluted in isotonic buffer solution which...Read more...

Merck's V920  (rVSVΔG-ZEBOV-GP)  candidate vaccine is a prime/boost candidate vaccine based on Ad26- and MVA-vectored components (Ad26.ZEBOV/MVA-BN-Filo) and the Ad5-EBOV candidate vaccine.

This...Read more...

VARIVAX is a vaccine indicated for active immunization for the prevention of varicella (ChickenPox) in individuals 12 months of age or older. Each dose is approximately 0.5 mL after reconstitution and is administered by subcutaneous injection.Read more...

Vaxchora is a vaccine indicated for active immunization against disease caused by Vibrio cholerae serogroup O1 in adults 18 through 64 years of age traveling to cholera-affected areas.Read more...

VLA15 is a multivalent vaccine that targets the outer surface protein A (OspA) of Borrelia and is under Fast Track Designation by the Food and Drug Administration (FDA). 

On December 17, 2018, Valneva SE announced the initiation of the ...Read more...

VXA-G1.1-NN is an Oral Vaccine Tablet addressing Norovirus.

The clinical trial is a Phase 1, Randomized, Double-Blind, Placebo-controlled, Dose-ranging Trial to Determine the Safety and Immunogenicity of an...Read more...